ASCOT Trial

@ascot_trial

AustralaSian COVID-19 Trial: A clinical trial that will generate clinical evidence about treatment for COVID-19 that can be applied during the pandemic.

ascot-trial.edu.au Joined April 2020

8 Following 303 Followers 73 Posts

Latest posts 5

ASCOT Trial @ascot_trial Feb 14, 2024

Clinician perceptions of research priorities for the management of noncritically ill patients admitted to hospital with SARS‐CoV‐2 infection - @ascot_trial Internal Medicine Journal onlinelibrary.wiley.com/doi/10.1111/im…

onlinelibrary.wiley.com Clinician perceptions of research priorities for the management of noncritically ill patients... The changing phenotype of coronarvirus disease 2019 (COVID-19) may quickly render guideline-recommended interventions obsolete. We developed a 40-question clinician survey in consultation with the...

ASCOT Trial @ascot_trial Jan 25, 2023

Please join ASCOT CIs, @syctong & @ZoeMcquilten, for a #TwitterSpaces event hosted by @NEJMEvidence about how the @ascot_trial changed the Anticoagulation Domain to adapt to new evidence about #anticoagulation strategies for COVID-19.

NEJM Evidence @NEJMEvidence Jan 23, 2023

Wondering how to adapt a trial when new data come out midway through it? The ASCOT Team did this for Covid-19 #anticoagulation strategies. Learn about the @ascot_trial design on #TwitterSpaces with @ZoeMcquilten & @syctong on 01/25 at 3PM EST. Sign up: x.com/i/spaces/1gqGv…

View quoted post on X

ASCOT Trial @ascot_trial Dec 13, 2022

ASCOT CI @ZoeMcquilten presenting the results of the Anticoagulation Domain at #ASH22. Go Zoe!

Erica Wood @erica_m_wood Dec 10, 2022

Congratulations @ZoeMcquilten, @syctong and all @ascot_trial study investigators, sites, staff and supporters
Anticoagulation domain results presented at #ASH22 today, and just published in @NEJMEvidence
doi.org/10.1056/EVIDoa…

View quoted post on X

ASCOT Trial @ascot_trial Dec 13, 2022

Read the thread below from ASCOT CI @syctong explaining the outcomes and importance of the results in our recent publication in @NEJMEvidence ⬇⬇⬇

ASCOT Trial @ascot_trial Dec 13, 2022

The results from the Anticoagulation Domain have been published in @NEJMEvidence showing intermediate dose anticoagulation had an 86% probability of being better than low dose in non-critically ill patients with COVID-19. ➡eviden.cc/3uyz0fB

evidence.nejm.org Anticoagulation Strategies in Non–Critically Ill Patients with Covid-19 Optimal thromboprophylaxis for hospitalized patients with coronavirus disease 2019 (Covid-19) is uncertain. In an open-label, adaptive platform trial, we randomly assigned hospitalized adults with ...

NEJM Evidence @NEJMEvidence Dec 10, 2022

In this RCT, investigators compared low-, intermediate-, and therapeutic-dose anticoagulation, as well as low-dose plus aspirin, in a diverse group of patients with Covid-19 in high-, low-, and middle-income countries. eviden.cc/3uyz0fB

#IDTwitter #ARDS #CriticalCare

View quoted post on X